Tax Hike Re-Pricing Slams Small Pharma and Gx Players, Impact Milder for Big Firms: Survey

Large pharmaceutical makers will dodge a major hit from Japan’s ad-hoc re-pricing associated with the consumption tax hike in October, which will likely put a more serious dent on smaller peers and companies relying heavily on their generic franchises, according...read more